Get the Stockscreener App
2.48
0.40%
0.010
After Hours:
2.52
0.04
+1.61%
Orasure Technologies Inc stock is traded at $2.48, with a volume of 500.05K.
It is up +0.40% in the last 24 hours and down -0.40% over the past month.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
See More
Previous Close:
$2.47
Open:
$2.51
24h Volume:
500.05K
Relative Volume:
0.78
Market Cap:
$177.90M
Revenue:
$405.47M
Net Income/Loss:
$53.66M
P/E Ratio:
3.4444
EPS:
0.72
Net Cash Flow:
$131.28M
1W Performance:
+0.40%
1M Performance:
-0.40%
6M Performance:
-19.48%
1Y Performance:
-33.69%
1-Day Range:
$2.44
$2.51
1-Week Range:
$2.33
$2.51
52-Week Range:
$2.08
$4.22
Orasure Technologies Inc Stock (OSUR) Company Profile
Name
Orasure Technologies Inc
Sector
Industry
Phone
(503) 641-6115
Address
220 E FIRST ST, BETHLEHEM, PA
Compare OSUR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OSUR
Orasure Technologies Inc
|
2.48 | 177.18M | 405.47M | 53.66M | 131.28M | 0.72 |
|
ISRG
Intuitive Surgical Inc
|
592.85 | 200.78B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
205.36 | 56.69B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
81.81 | 39.62B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
249.19 | 35.81B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
MDLN
Medline Inc
|
39.77 | 30.70B | 27.43B | 1.27B | 1.01B | 1.5829 |
Orasure Technologies Inc Stock (OSUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-03-23 | Resumed | Evercore ISI | In-line |
| Sep-22-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-21-20 | Initiated | Evercore ISI | Outperform |
| Aug-10-20 | Initiated | Citigroup | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
| Aug-07-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-25-20 | Initiated | Lake Street | Buy |
| Apr-21-20 | Resumed | Stephens | Equal-Weight |
| Oct-23-18 | Resumed | Raymond James | Mkt Perform |
| Jul-16-18 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-02-17 | Downgrade | Jefferies | Buy → Hold |
| Feb-09-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-13-16 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-05-15 | Reiterated | Mizuho | Buy |
| May-07-15 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jan-23-15 | Reiterated | Mizuho | Buy |
| Jun-12-14 | Reiterated | Canaccord Genuity | Buy |
| Jun-11-14 | Reiterated | Mizuho | Buy |
| Dec-21-12 | Initiated | Mizuho | Buy |
| Aug-08-12 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jul-05-12 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-27-12 | Initiated | JMP Securities | Mkt Outperform |
View All
Orasure Technologies Inc Stock (OSUR) Latest News
OraSure seeking FDA approval for pair of products - WFMZ.com
OraSure Files for FDA Review of Molecular Self-Test & Colli-Pee Device - sharewise.com
OraSure (OSUR) Seeks FDA Approval for New Diagnostic Solutions - GuruFocus
OraSure Seeks FDA Clearance for New STI Tests - TipRanks
OraSure submits FDA applications for rapid STI test and collection device - Investing.com India
OraSure Technologies, Inc. Submits FDA Applications for Rapid Self-Test for STIs and At-Home Urine Collection Device - Quiver Quantitative
OraSure Technologies Inc Submits FDA Applications for Diagnostic Devices - TradingView — Track All Markets
OraSure submits two diagnostic tests to FDA for clearance - StreetInsider
OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review - Yahoo Finance
Is OraSure Technologies Inc. (EP3) stock good for long term investingJuly 2025 Catalysts & Consistent Profit Trade Alerts - Улправда
Investment Recap: Can OraSure Technologies Inc. stock surprise with earnings upsideWeekly Risk Report & Daily Chart Pattern Signal Reports - Улправда
Can OraSure Technologies Inc. stock maintain operating margins2025 Technical Patterns & Low Risk High Reward Ideas - Улправда
Can OraSure Technologies Inc. stock surprise with earnings upsideJuly 2025 Catalysts & Low Risk High Reward Ideas - Улправда
Hedge fund confirms boardroom battle brewing at OraSure - WFMZ.com
OraSure Technologies Earnings Notes - Trefis
OraSure Technologies Issues Statement Regarding Altai Capital?s Intent to Nominate Director Candidates - marketscreener.com
OraSure issues statement regarding Altai's intent to nominate director candidates - marketscreener.com
OraSure (OSUR) Responds to Altai Capital's Board Nominee Proposa - GuruFocus
Altai Capital to nominate directors to OraSure board amid concerns By Investing.com - Investing.com Nigeria
Altai Capital to nominate two board candidates at OraSure Technologies By Investing.com - Investing.com Nigeria
OraSure Confirms Altai Capital's Intention of Board Nominations - marketscreener.com
Altai Capital to nominate two board candidates at OraSure Technologies - Investing.com
OraSure Technologies Confirms Altai Capital's Nomination of Board Candidates Ahead of 2026 Annual Meeting - Quiver Quantitative
OraSure Technologies Issues Statement Regarding Altai Capital’s Intent to Nominate Director Candidates - StreetInsider
Altai Capital Announces Intention to Nominate Candidates for Election to OraSure Board - marketscreener.com
Altai Capital Nominates Two Candidates for OraSure (OSUR) Board - GuruFocus
Altai Capital to nominate two candidates for OraSure board - marketscreener.com
Altai Capital plans to nominate two directors to OraSure's board (OSUR:NASDAQ) - Seeking Alpha
Altai Capital to nominate directors to OraSure board amid concerns - Investing.com
Altai Capital Management Announces Intention to Nominate Two Highly-Qualified Candidates for Election to OraSure Board of Directors - Business Wire
Rapid Medical Diagnostics Market Analysis 2025: Outlook in GCC - openPR.com
At-Home Syphilis Testing Market - Future Market Insights
OraSure Technologies, Inc. $OSUR Shares Sold by American Century Companies Inc. - MarketBeat
What drives OraSure Technologies Inc stock priceAI-Driven Market Analysis & Free Triple Digit Wealth Increase - earlytimes.in
Is OraSure Technologies Inc. stock oversold or undervaluedBreakout Watch & High Yield Stock Recommendations - Newser
How sustainable is OraSure Technologies Inc. stock dividend payout2025 Price Action Summary & Smart Investment Allocation Tips - Newser
How OraSure Technologies Inc. (EP3) stock correlates with oil markets2025 Market WrapUp & Precise Buy Zone Identification - Newser
Why OraSure Technologies Inc. (EP3) stock could rally strongly2025 EndofYear Setup & Risk Adjusted Swing Trade Ideas - Newser
What insider trading reveals about OraSure Technologies Inc. stockEarnings Performance Report & Weekly Stock Performance Updates - Newser
Systematic Financial Management LP Increases Holdings in OraSure Technologies, Inc. $OSUR - MarketBeat
Why OraSure Technologies Inc. stock could rally in 2025Insider Selling & High Win Rate Trade Tips - Newser
Shareholder Aspinall Files To Sell 89,716 Of OraSure Technologies Inc [OSUR] - TradingView — Track All Markets
Improving Women's Health with Rapid STI Testing - Fierce Healthcare
Can OraSure Technologies Inc. (EP3) stock beat analyst consensus2025 Trading Volume Trends & Real-Time Market Trend Scan - Newser
Dir Gagliano Buys 2,100 ($5K) Of OraSure Technologies Inc [OSUR] - TradingView — Track All Markets
Orasure Technologies Inc Stock (OSUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Orasure Technologies Inc Stock (OSUR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gagliano Nancy J | Director |
Nov 28 '25 |
Buy |
2.37 |
2,100 |
4,982 |
160,254 |
| Gagliano Nancy J | Director |
Feb 27 '25 |
Buy |
3.08 |
12,750 |
39,270 |
91,524 |
| EGLINTON MANNER CARRIE | President & CEO |
Feb 28 '25 |
Buy |
3.49 |
28,670 |
100,027 |
1,288,334 |
| EGLINTON MANNER CARRIE | President & CEO |
Feb 27 '25 |
Buy |
3.15 |
78,625 |
247,378 |
1,259,664 |
| Kenny John P. | Director |
Feb 27 '25 |
Buy |
3.17 |
47,659 |
151,217 |
70,915 |
| McGrath Kenneth J | Chief Financial Officer |
Feb 27 '25 |
Buy |
3.15 |
64,000 |
201,683 |
371,013 |
| Marmora Lelio | Director |
Feb 27 '25 |
Buy |
3.06 |
7,000 |
21,420 |
67,720 |
4.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):